BEVACIZUMAB

作品数：440被引量：1270H指数：13
导出分析报告
相关领域：医药卫生更多>>
相关作者：宋艳萍丁琴黎晓新陈中山王雨生更多>>
相关机构：北京大学中山大学广州军区武汉总医院第四军医大学西京医院更多>>
相关期刊：更多>>
相关基金：国家自然科学基金湖北省科技攻关计划上海市教育委员会重点学科基金广州市医药卫生科技项目更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Atezolizumab and bevacizumab combination in advanced hepatocellular carcinoma patients:The imperative for safety assessment studies
《World Journal of Clinical Cases》2025年第9期56-59,共4页Mina Tharwat Ahmed Tawheed Mohamed El-Kassas 
Hepatocellular carcinoma(HCC)is the most prevalent cancer of the hepatobiliary tract and the third leading cause of cancer-related mortality worldwide.Atezolizumab and bevacizumab combination is currently considered a...
关键词：Hepatocellular carcinoma Atezolizumab BEVACIZUMAB HEMORRHAGE Side effects 
Two treatment methods for hepatocellular carcinoma:Lenvatinib or bevacizumab combined with sintilimab and interventional therapy
《World Journal of Gastroenterology》2025年第10期164-167,共4页Fei-Yu Zhao Xiao-Ming Zhang Nian-Song Qian 
In their study,Han et al compared the efficacy of bevacizumab plus sindilizumab plus interventional therapy with that of lenvatinib plus sindilizumab plus interventional therapy for patients with intermediate and adva...
关键词：Hepatocellular carcinoma BEVACIZUMAB Lenvatinib Sintilimab Interventional treatment 
Addition of SHR-1701 to first-line capecitabine and oxaliplatin(XELOX) plus bevacizumab for unresectable metastatic colorectal cancer
《Signal Transduction and Targeted Therapy》2025年第1期340-349,共10页Miao-Zhen Qiu Yuxian Bai Jufeng Wang Kangsheng Gu Mudan Yang Yifu He Cheng Yi Yongdong Jin Bo Liu Feng Wang Yu-kun Chen Wei Dai Yingyi Jiang Chuanpei Huang Rui-Hua Xu Hui-Yan Luo 
supported by Jiangsu Hengrui Pharmaceuticals and the following grants:the National Natural Science Foundation of China(NSFC:82321003,82173128,82073377,81930065);the Natural Science Foundation of Guangdong(2021A1515012439);Guangdong Basic and Applied Basic Research Foundation(2024B1515020120);the CAMS Innovation Fund for Medical Sciences(CIFMS:2019-I2M-5-036);Additional funding was provided by the Cancer Innovative Research Program of Sun Yat-sen University Cancer Center(CIRP-SYSUCC-0004).
This phase 2/3 trial (NCT04856787) assessed the efficacy and safety of SHR-1701, a bifunctional protein targeting PD-L1 and TGF-β,in combination with BP102 (a bevacizumab biosimilar) and XELOX (capecitabine plus oxal...
关键词：BEVACIZUMAB colorectal SHR 
Alternating modified CAPOX/CAPIRI plus bevacizumab in untreated unresectable metastatic colorectal cancer:a phase 2 trial
《Signal Transduction and Targeted Therapy》2025年第1期321-327,共7页Sheng Li Xiaoyou Li Hanfeng Xu Jiayuan Huang Jingni Zhu Ying Peng Jun Bao Liangjun Zhu 
supported by Beijing Science and Technology Innovation Medical Development Foundation(grant no.KC2021-JX-0186-106).
Previous studies showed encouraging efficacy of alternating FOLFOX/FOLFIRI for metastatic colorectal cancer(mCRC).This phase 2 trial(NCT04324476)aimed to evaluate efficacy and safety of alternating modified CAPOX(cape...
关键词：BEVACIZUMAB UNTREATED COLORECTAL 
Systematic review:bevacizumab combined with radiotherapy regimen in NSCLC patients,modulating VEGF/VEGFR2 signaling
《Journal of Chinese Pharmaceutical Sciences》2024年第12期1137-1145,共9页Zhangpeng Song Feng Zhou Yangyong Zhang Jie Zhang Yuan Feng 
To assess the efficacy of radiotherapy combined with bevacizumab compared to radiotherapy alone in patients with non-small cell lung cancer(NSCLC)and to explore its impact on anti-tumor neovascularization,we conducted...
关键词：one Bevacizumab combined with radiotherapy NSCLC VEGF VEGFR Clinical effect 
Comment on“Clinical outcomes and histologic findings of patients with hepatocellular carcinoma with durable partial response or durable stable disease after receiving atezolizumab plus bevacizumab”
《iLIVER》2024年第4期64-65,共2页Binghua Li Qiang Wang Weiwei Hu Huan Li Peng Yan Yajuan Cao Decai Yu 
supported by grants from the National Natural Science Foundation of China(Nos.82372834 and 82173129);the Jiangsu Outstanding Youth Foundation(BK20240119).
We read with great interest the recent article by Shen et al.[1],which provides valuable insights into the outcomes and histopathologic characteristics of hepatocellular carcinoma(HCC)patients treated with atezolizuma...
关键词：(PCR) PATIENTS HEPATOCELLULAR 
The Observation of Clinical Efficacy and Safety of De-Platinum-Based Pleural Perfusion in the Treatment of Malignant Pleural Effusion and Its Correlation with the Expression of VEGF in Pleural Fluid
《Journal of Cancer Therapy》2024年第12期432-445,共14页Peng Wang Chufeng Zhang Pengpeng Hao Shuyan Wang Rongguang Zhu Juanjuan Li Yiming Bi 
Background: Malignant pleural effusion (MPE) is the most common complication of advanced NSCLC. Infusion chemotherapy is currently one of the most common intracavitary treatments for MPE. Unfortunately, there is no de...
关键词：BEVACIZUMAB Brucea Javanica Oil Emulsion Injection Advanced Lung Adenocarcinoma Malignant Pleural Effusion 
Lenvatinib,sintilimab combined interventional treatment vs bevacizumab,sintilimab combined interventional treatment for intermediate-advanced unresectable hepatocellular carcinoma被引量：2
《World Journal of Gastroenterology》2024年第43期4620-4635,共16页Ru-Yu Han Lei-Juan Gan Meng-Ran Lang Shao-Hua Ren Dong-Ming Liu Guang-Tao Li Ya-Yue Liu Xin-Di Tian Kang-Wei Zhu Li-Yu Sun Lu Chen Tian-Qiang Song 
Supported by The National Natural Science Foundation of China,No.82173317;The Scientific Research Projects of Tianjin Education Commission,No.2022KJ227;The Doctoral Start-up Fund of Tianjin Medical University Cancer Institute&Hospital,No.B2208.
BACKGROUND Bevacizumab and sintilimab combined interventional treatment(BeSiIT)and L envatinib and sintilimab combined interventional treatment(LeSiIT)are two commonly used therapeutic regimens for intermediate-advanc...
关键词：Hepatocellular carcinoma Molecular targeted therapy IMMUNOTHERAPY Interventional treatment Propensity score matching 
Vascular endothelial growth factor pathway’s influence on bevacizumab efficacy in metastatic colorectal cancer treatment
《World Journal of Gastrointestinal Oncology》2024年第11期4514-4517,共4页Yuan Qin Fu-Yuan Ma Zhi Zhang Chen-Hao Zhao Biao Huang 
The Natural Science Foundation of Zhejiang Province,No.LQ23H050005;The Scientific Research Project of Zhejiang Provincial Education Department,No.Y202250731 and No.Y202353130;China Students’Innovation and Entrepreneurship Training Program,No.202310338044;China Postdoctoral Science Foundation,No.2022M721720.
In this article,an article published in the World Journal of Gastrointestinal Oncology,which focuses on whether the expression of programmed death-ligand 1(PD-L1)affects the effectiveness of chemotherapy regimens,incl...
关键词：BEVACIZUMAB CHEMOTHERAPY Metastatic colorectal cancer PD-1/PD-L1 axis Therapeutic approach Vascular endothelial growth factor 
Clinical evaluation of sintilimab in conjunction with bevacizumab for advanced colorectal cancer with microsatellite stable-type after failure of first-line therapy
《World Journal of Gastrointestinal Surgery》2024年第10期3277-3287,共11页Liang Wang Yong-Zhi Diao Xin-Fu Ma Yu-Shuang Luo Qi-Jing Guo Xiao-Qian Chen 
Supported by the 2021 Key Topic of the Qinghai Provincial Health System-Guiding Plan Topic,No.2021-WJZDX-43.
BACKGROUND At present,immune checkpoint inhibitors(ICIs)remain the 1st-line therapy me-thod for patients suffering from high microsatellite instability/deficient misma-tch repair metastatic colorectal cancer(mCRC).How...
关键词：Immune checkpoint inhibitors BEVACIZUMAB Colorectal cancer Cytotoxic T lymphocytes Tumor-associated macrophages Cancer-associated fibroblasts 
全选清除导出
共45页<12345678910>
检索报告 对象比较 聚类工具 使用帮助 返回顶部